The 39th annual conference of the Society of Neuroscience drew some 30.

Researchers have demonstrated that memantine, a neuroprotective drug, may reduce the impulsive and addictive behavior associated with binge eating. The Boston University College of Medicine study, which appears on-line in Neuopsychopharmacology, also discovered that a particular area in the brain, the nucleus accumbens, which is in charge of addictive behaviors, facilitates the consequences of memantine. Binge-consuming disorder is usually a prevalent illness in the us, affecting more than 10 million people. It is characterized by periods of extreme uncontrolled consumption of meals, followed by uncomfortable feelings and fullness of self-disgust. New evidence indicates that adjustments in brain chemistry reflecting the addictive nature of bingeing may parallel medication and alcoholic beverages addiction.Review ibudilast trial results, previously summarized in MediciNova’s pr announcements and a demonstration at the 2008 WCTRIMS meeting, and poses that ibudilast’s apparent clinical benefit may be linked to a neuroprotective actions.D., Cleveland Clinic, entitled Principal neuroprotection: The Holy Grail of multiple sclerosis therapy . Fox defined the challenges of therapeutically impacting the disabling procedure for neurodegeneration in principal progressive and secondary progressive types of multiple sclerosis. Related StoriesAdvances entirely mount mind imaging: an interview with Patrick Myles, President, Huron Digital PathologyStudy shows guarantee for developing targeted remedies for multiple sclerosisStudy shows how dietary fatty acids affect advancement and progression of multiple sclerosisYuichi Iwaki, M.D., Ph.D., President and CEO of MediciNova mentioned that we are pleased that the neurological community is normally recognizing the potential benefits and exclusive positioning of MN-166 as a drug therapy in treating disability progression in a serious illness like multiple sclerosis.